(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of -13.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.71%.
Immatics Nv's revenue in 2025 is $151,313,953.On average, 2 Wall Street analysts forecast IMTX's revenue for 2025 to be $5,106,107,092, with the lowest IMTX revenue forecast at $3,877,748,273, and the highest IMTX revenue forecast at $6,334,465,910. On average, 2 Wall Street analysts forecast IMTX's revenue for 2026 to be $5,651,909,278, with the lowest IMTX revenue forecast at $4,157,335,139, and the highest IMTX revenue forecast at $7,146,483,417.
In 2027, IMTX is forecast to generate $14,410,879,555 in revenue, with the lowest revenue forecast at $14,410,879,555 and the highest revenue forecast at $14,410,879,555.